Phase 2 N=15 Randomized Double-blind

Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder

Bottom Line

View on ClinicalTrials.gov: NCT01100255 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2016

Primary outcome: Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. — 0; 5 participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Ketamine infusion (Drug); Saline (Other)
Age: Adult · 18+ yrs
Sex: All
Sponsor: New York State Psychiatric Institute
Primary completion: Dec 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.	0; 5	—

Summary

In this study investigators are studying the effects of a drug called ketamine on the symptoms of Obsessive-compulsive disorder (OCD).

Eligibility Criteria

Inclusion Criteria

Age 18-55
Physically healthy and not currently pregnant
Primary Diagnosis of OCD
Sufficient severity of symptoms
Able to provide consent

Exclusion Criteria

Psychiatric conditions that make participation unsafe
Currently on psychotropic medication
Medical conditions that make participation unsafe
Allergy to ketamine
Any metal in the body

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01100255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.